Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I was less impressed with the results and surprised by early share price rise - that seems to be reversing now
I am sure COVID has impacted but profit/cash seem lower
Also todays purchase seems to lack any detail on financial impact / pay back period etc etc
Good job we are being taken over!
This opens up the balancing mechanism for GRID (which means more revenue perhaps)
https://www.nationalgrideso.com/news/new-it-interface-widens-balancing-mechanism-access-smaller-generators?utm_source=twitter&utm_medium=social&utm_campaign=balancing_the_grid&utm_content=article
Solid results - good growth in cash - BUT like a lot of small companies some of the metrics like P/E look very ambitious. Lets see if they can step up the performance in the next 12 months.......
there will be a lot of people thinking this revenue / profit increase is only short term due to the volatility of the markets currently - I suspect we have 18months - 2 years before things calm down myself so trading volumes will remain high medium term
FYI I also hold PLUS500 and it has seen the same massive uplift on volume / customers / revenue / profit as IGG
Anyone like to comment on the results?
To me they seem poor APART from the investment in Clearplay which (due to value being re-stated) delivered more than £50M. The other services offered all seemed to decline......
So perhaps the investments will be more important than their own services moving forward
Love any other thoughts you have
Seems that business is returning to normal -- what we don not know yet is whether the customers that took payment holidays during shut down will be able to pay back money owed to Duke.
Share price should move upwards as we head into Q3 and Q4
Has anyone got access to the FT and able to look at this news item - is it NCYT?
https://twitter.com/gjbrandon/status/1303961930147811329
The UK government has drawn up plans to carry out up to 10 million covid-19 tests a day by early next year as part of a huge £100bn (€110bn; $130bn) expansion of its national testing programme, documents seen by The BMJ show.
The internal correspondence reveals that the government is prepared to almost match what it spends on the NHS in England each year (£130bn) to fund mass testing of the population “to support economic activity and a return to normal life” under its ambitious Operation Moonshot programme.
A briefing memo sent to the first minister and cabinet secretaries in Scotland, seen by The BMJ, says that the UK-wide Moonshot programme is expected to “cost over £100bn to deliver.” If achieved, the programme would allow testing of the entire UK population each week.
A separate PowerPoint presentation prepared for the government by the global management consulting firm Boston Consulting Group, also seen by The BMJ, says the plans had the potential to grow the UK’s testing capacity from the current 350?000 a day to up to 10 million tests a day by early 2021.
Critics have already rounded on the plans as “devoid of any contribution from scientists, clinicians, and public health and testing and screening experts,” and “disregarding the enormous problems with the existing testing and tracing programmes.”
The leaked documents reveal a heavy reliance on the private sector to achieve the mass testing and give details of “letters of comfort” that have already been signed with companies to reach three million tests a day by December. Firms named are GSK for supplying tests, AstraZeneca for laboratory capacity, and Serco and G4S for logistics and warehousing.
The UK government has drawn up plans to carry out up to 10 million covid-19 tests a day by early next year as part of a huge £100bn (€110bn; $130bn) expansion of its national testing programme, documents seen by The BMJ show.
The internal correspondence reveals that the government is prepared to almost match what it spends on the NHS in England each year (£130bn) to fund mass testing of the population “to support economic activity and a return to normal life” under its ambitious Operation Moonshot programme.
A briefing memo sent to the first minister and cabinet secretaries in Scotland, seen by The BMJ, says that the UK-wide Moonshot programme is expected to “cost over £100bn to deliver.” If achieved, the programme would allow testing of the entire UK population each week.
A separate PowerPoint presentation prepared for the government by the global management consulting firm Boston Consulting Group, also seen by The BMJ, says the plans had the potential to grow the UK’s testing capacity from the current 350?000 a day to up to 10 million tests a day by early 2021.
Critics have already rounded on the plans as “devoid of any contribution from scientists, clinicians, and public health and testing and screening experts,” and “disregarding the enormous problems with the existing testing and tracing programmes.”
The leaked documents reveal a heavy reliance on the private sector to achieve the mass testing and give details of “letters of comfort” that have already been signed with companies to reach three million tests a day by December. Firms named are GSK for supplying tests, AstraZeneca for laboratory capacity, and Serco and G4S for logistics and warehousing.
The UK government has drawn up plans to carry out up to 10 million covid-19 tests a day by early next year as part of a huge £100bn (€110bn; $130bn) expansion of its national testing programme, documents seen by The BMJ show.
The internal correspondence reveals that the government is prepared to almost match what it spends on the NHS in England each year (£130bn) to fund mass testing of the population “to support economic activity and a return to normal life” under its ambitious Operation Moonshot programme.
A briefing memo sent to the first minister and cabinet secretaries in Scotland, seen by The BMJ, says that the UK-wide Moonshot programme is expected to “cost over £100bn to deliver.” If achieved, the programme would allow testing of the entire UK population each week.
A separate PowerPoint presentation prepared for the government by the global management consulting firm Boston Consulting Group, also seen by The BMJ, says the plans had the potential to grow the UK’s testing capacity from the current 350?000 a day to up to 10 million tests a day by early 2021.
Critics have already rounded on the plans as “devoid of any contribution from scientists, clinicians, and public health and testing and screening experts,” and “disregarding the enormous problems with the existing testing and tracing programmes.”
The leaked documents reveal a heavy reliance on the private sector to achieve the mass testing and give details of “letters of comfort” that have already been signed with companies to reach three million tests a day by December. Firms named are GSK for supplying tests, AstraZeneca for laboratory capacity, and Serco and G4S for logistics and warehousing.
1) COPD - slightly ambivalent initial results but some areas for optimism. No side effects/bad reactions seen statistically. I would assume (but not stated) that trial is ongoing and we will get further results from it as treatments and recoveries progress. COPD is actually a bigger market than CV19 in the longer term so hopefully this will come good for SNG.
2) CV19 - given COPD results SNG are now focused for short term on treatment and on expedited approvals to allow sales. Sensible decision given the great trial results for CV19.
Suspect a positive day today but not massive uplift in share price.
Pricing seems to be correct for a sell at 13:03.......but it is massive
02-Sep-20 13:03:35 2.85 15,673,198 Sell* 2.80 2.95 446.69k
The cash generation and profit seem very good - dividend growing strongly - the forward view statements are not strong but seem confident
yes it would fit nicely into the business model BUT it is all about what we have to pay to get it..........
great to get this fab' news on what's normally a quite day of the week for news.........now I have to decide what to do with my holding in Integumen and my future Integumen shares from this takeover. Should I say or should I go? (probably something in between in reality)
yes I've just noticed that the market seems happy with the results - interestingly it was down about 2% for several hours this morning
The cloud on the Horizon is the situation in Belarus where BGEO has business - I am not sure what % of their total income comes from Belarus though.
I have bought back in this morning so lets see. I am hoping for a good dividend in 2021 perhaps including some money from the 2019 dividend which has not been paid.
These results look good to me.......they had one bad month due to covid and then two months recovering.
I sold out of BGEO at the start of 2020 and may well invest again on the basis that dividends will start again in 2021, and thr share price will be going up
Anyone have any views?
This is from twitter just now.......
JUST IN: Dr. Anthony Fauci, confirms to CNN that scientists at the National Institute of Allergy and Infectious Diseases are working to create a strain of #coronavirus that could be used in human challenge trials of a Covid-19 vaccine.
Fauci, director of the NIAID, described this approach as a "Plan D" – and the work is still preliminary.
Human challenge trials are typically used when a virus is not widely circulating – the #coronavirus is – so this approach may not be necessary, according to Fauci.
https://twitter.com/AnaCabrera/status/1294250229286547457?s=20
Wonder if the UK are looking at this and whether it would enable CV19 challenge studies in ORPH facilities